Menu
  • Join
  • Login
  • Contact
 

Search abstracts


CONTRIBUTION OF COMMUNITY PHARMACIES IN THE PREVENTION AND CONTROL OF BENIGN PROSTATIC HYPERPLASIA

  • At: 2019 FIP Congress in AbuDhabi (United Arab Emirates)
  • Type: Presentation
  • By: BRITO, Joana (Farmácias Holon, Portugal)
  • Co-author(s): Joana Brito: Projects and Services, Farmácias Holon,
    Beatriz Mónico: Projects and Services, Farmácias Holon,
    Ana Macedo: Projects and Services, Farmácias Holon,
    Isabel Guerreiro: Projects and Services, Farmácias Holon,
    Maria Mendes: Projects and Services, Farmácias Holon,
    Nuno Machado: Projects and Services, Farmácias Holon,
  • Abstract:

    Background

    Benign Prostatic Hyperplasia (BPH) is one of the most frequent pathologies in men over 50 years old and its prevalence increases progressively with age. The uncomfortable low urinary tract symptoms (LUTS) occur in about 30% of men over 65 years old. These symptoms have a huge impact on the quality of life (QoL), being one of the major..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 21 September 2019

FIP Congresses